article thumbnail

Biotech leader champions targeted cancer treatments and diversity

Drug Target Review

As the CEO of iOnctura, an innovative oncology biopharmaceutical company she co-founded in 2017, Catherine has played a key role in advancing the development of highly targeted small molecules aimed at revolutionising cancer treatment. So, with a huge amount of courage and commitment, I co-founded iOnctura in 2017.

article thumbnail

2025 Merkin Prize in Biomedical Technology awarded to pioneers of CAR T-cell therapy

Broad Institute

A similar CAR from another company, Kite Pharmaceuticals (now a Gilead company), was approved by the FDA in 2017 as the second commercial CAR T-cell therapy. After their clinical results, their technology was licensed to Juno Therapeutics (later acquired by Bristol Myers Squibb.)

Therapies 119
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Time for change: non-human primates in drug research

Drug Target Review

Lee TYT, Coles JG, Maynes JT. iPSC-cardiomyocytes in the preclinical prediction of candidate pharmaceutical toxicity. Front Pharmacol. 2024;15:1308217. Ekins S, Clark AM. In silico toxicology: computational methods for predicting toxicity. Toxicology Research. Low LA, Tagle DA. Organs-on-chips: Progress, challenges, and future directions.

article thumbnail

Forging a Path Forward for Substance Abuse Potential Studies With the Cross-Company Abuse Liability Council By Beatrice Setnik, PhD

Alta Sciences

Despite having a final FDA guidance issued in 2017 , evolving drug development and treatment modalities continue to prompt important dialogue to adapt existing methods. One example is the recent interest in psychedelics for the treatment of psychiatric disorders, including major depressive disorder.

article thumbnail

Vamorolone

New Drug Approvals

2017, 82, 11961−11980. (77) 2017, 82,11961−11980. Archived from the original on 7 October 2017. Retrieved 2 July 2017. World Health Organization (2017). Vamorolone targets dual nuclear receptors to treat inflammation and dystrophic cardiomyopathy. Alliance 2019, 2, No. e201800186. (76)Boger, 77) Reeves, E.

FDA 62
article thumbnail

Can Plants Really “See”?

Codon

In a 2017 study, the duo offered two possible explanations : Either Boquila had evolved a heightened ability to detect volatile chemicals emitted by nearby vegetation, or it was somehow borrowing genetic information from nearby microbes to camouflage itself.

article thumbnail

In vivo CAR T: Faster, cheaper, and more effective cancer care

Drug Target Review

Since their first approvals in 2017, autologous CAR T-cell therapies have revolutionised the treatment of blood cancers, offering hope where previous options had failed. With the first approvals of CD19 CAR T-cells in 2017, treatment outcomes for patients improved dramatically.